Global Rosacea Drugs Market Overview:
Rosacea is a disorder involving chronic inflammation of the cheeks, nose, chin, forehead, or eyelids. It may cause redness, vascularity, swelling or hyperplasia, or skin eruptions similar to acne. The main symptoms of rosacea are facial flushing, irritated skin, and pimples. Other symptoms include blushing easily and eye problems.
- Rising Awareness about Rosacea
- High Demand for Effective Treatment for Parkinson's Disease
- Increased Research and Development Activities
- Side Effects of the Drugs
- Growth in the Geriatric Population Worldwide
- Growth in the Healthcare Sector
- Multiple Patent Expiries Bring a Significant Number of Generic Products
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Nestle Skin Health (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Mylan (United States), Bayer (Germany), Sun Pharma (India), Perrigo (United States), Bausch Health (Canada), GSK (United Kingdom) and Pfizer (United States). Additionally, following companies can also be profiled that are part of our coverage like Allergan (Ireland) and Almirall (Spain). Analyst at AMA Research see Global Players to retain maximum share of Global Rosacea Drugs market by 2026. Considering Market by Mode of Administration, the sub-segment i.e. Topical will boost the Rosacea Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Drugs Stores will boost the Rosacea Drugs market.
In Sept 2020, Sol-Gel Technologies, Ltd. announced that its New Drug Application (NDA) for Epsolay® (benzoyl peroxide), an investigational proprietary topical cream for the treatment of inflammatory lesions of rosacea, containing 5% encapsulated benzoyl peroxide, has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for Epsolay is April 26, 2021.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Rosacea Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Rosacea Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Rosacea Drugs, Suppliers and Distributors of Rosacea Drugs, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.